BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

TcLand Expression's Board of Directors Appoints Highly Qualified Personalized Medicine Expert Felix Frueh Phd, as New Board Member


4/19/2011 9:23:32 AM

Nantes, France, April 19, 2011 – TcLand Expression, a leading company focused on gene expression biomarkers in immunology and personalized medicine today announced the appointment of Felix Frueh PhD, as new member of the company’s Board of Directors.

"We are particularly honored that a personality like Felix Frueh has agreed to join TcLand Expression's Board of Directors. Felix is one of the rare worldwide pioneers in personalized medicine and was instrumental for the development of such discipline during his time at the FDA. He now holds a key role in Medco, making personalized medicine and companion diagnostics a reality in medical practice. His vision and in-depth understanding of the market opportunities will highly benefit TcLand Expression and will be fundamental for achieving our next development milestones", emphasized Alain Huriez, co-founder and Chief Executive Officer of the company.

"I am delighted to have been appointed as a member of the Board of TcLand. I am impressed by the scientific excellence of the company and its pioneering developments in the field of companion diagnostics. The company has all attributes of a worldwide leader in the development of algorithms critical for treatment decisions in therapeutic areas such as Rheumatoid Arthritis", stated Felix Frueh. “TcLand Expression is well positioned to have a major, significant and quantifiable impact on patients' needs in the field of personalized medicine", he concluded.

Felix Frueh is President of Medco Research Institute®, a division of Medco, the largest US Pharmacy Benefit Manager. In this function, Felix Frueh manages Medco’s expanding peer-reviewed research initiatives and collaborations in personalized medicine, comparative effectiveness research and clinical practice improvements, leveraging the newest developments in science to improve the safety and efficacy of prescription drug care. He is also responsible for the development of Medco’s Personalized Medicine Research Center, which is under construction in Whitestown, Indiana. Felix joined Medco in May 2008 to lead the company’s personalized medicine research and development organization.

Prior to joining Medco, Felix Frueh was Associate Director for Genomics at the U.S. Food and Drug Administration (FDA), where he built and led the core genomics review team in the Center for Drug Evaluation and Research (CDER), and chaired the first FDA-wide, interdisciplinary pharmacogenomics review group (IPRG). Prior to the FDA, he was Managing Partner at Stepoutside Consulting, LLC, and held senior positions at Transgenomic and Protogene Laboratories. Felix Frueh has published numerous peer-reviewed articles and is a frequent invited speaker at national and international conferences. He has been a member of various working groups on genetics and genomics at the FDA and at the Department of Health and Human Services (DHHS), and is a Member of the Board of the Personalized Medicine Coalition. His academic career includes a faculty appointment at the Departments of Pharmacology and Medicine at Georgetown University in Washington DC, and postdoctoral fellowships at Stanford University and the University of Basel, Switzerland, where he also received his Ph.D. in biochemistry.

About TcLand Expression

TcLand Expression is a recognized pioneer in the discovery, development and validation of gene expression biomarkers for unmet medical needs in immunology. The company benefits from an exceptional scientific and clinical environment. For more information, please visit our website: www.tcland-expression.com

Contacts

Alain Huriez, CEO

TcLand Expression

Phone: +33 2 40 35 89 99

ahuriez@tcland-expression.com

Caroline Carmagnol

ALIZE RP

+ 33 6 64 18 99 59

caroline@alizerp.com

Anne-Sophie Cosquéric

33 1 42 68 86 41

anne-sophie@alizerp.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES